Pharmaceutical Benefits Regulations (Amendment) (Cth)
Statutory
Rules 1949,
No. 44.
(
a )by omitting from sub-regulation (1.) the definition of “prescription” and inserting in its stead the following definitions:—
“‘prescription’ means a prescription for the supply of a pharmaceutical benefit;
‘prescription form’ means a prescription form supplied by the Commonwealth for the purposes of the Act;”; and
(
b ) by omitting paragraphs (a ) and (b )of sub-regulation (3.) and inserting in their stead the following paragraphs:—
“ (a )are in receipt of a grant for maintenance from a State; and“(
b )are certified to be public hospitals by the Minister of State of the State administering the laws of the State relating to public hospitals.”.
(
a ) by omitting sub-regulation (3.) and inserting in its stead the following sub-regulation:—“(3.) Except in the case of biological products, capsules of amyl nitrite, injections (other than rectal injections), pills, tablets for oral or hypodermic administration and vitamin solutions, each of the following variations, and each variation consisting of any combination of any of those variations, shall, for the purposes of sub-section (2.) of section 6 of the Act, be a permitted variation of any formula contained in the Commonwealth Pharmaceutical Formulary, namely:—
(
a )the reduction of the quantity of any ingredient or ingredients (other than the vehicle);(
b )the omission of any ingredient or ingredients (other than the vehicle);(
c )the increase in the quantity of an ingredient marked with an asterisk to a quantity not exceeding the maximum British Pharmacopoeia dose for that ingredient;
(
(
d )in the case of the formula for a mixture included in the section headed ‘1. GENERAL SECTION’—the inclusion of not more than two drugs (not being drugs included in the formula) specified in the Commonwealth Pharmaceutical Formulary in any list of allowable additions applicable to the formula, but so that the quantity of an included drug does not exceed the maximum quantity specified in that list;(
e ) in the ease of a formula to which the last preceding paragraph is not applicable—the inclusion of any one drug (not being a drug included in the formula) specified in the Commonwealth Pharmaceutical Formulary as an allowable addition applicable to the formula, but so that the quantity of the included drug does not exceed the quantity specified in the Formulary in relation to that formula;(
f ) the substitution for a syrup (other than ‘Syrup B.P.’) of a syrup specified in the Commonwealth Pharmaceutical Formulary in any list of allowable substitutes applicable to the formula;(
g )the substitution for an aromatic water (including chloroform water) of water or of an aromatic water specified in the Commonwealth Pharmaceutical Formulary in any list of allowable substitutes applicable to the formula;(
h )in the case of a formula for an ointment—any variation (including the omission, addition or substitution of an appropriate ingredient) of that part of the formula which comprises the ointment base.”; and(
b ) by omitting sub-regulation (4.).
“(2.) The Director-General may, for any reason which he thinks sufficient, permit any such application to be made otherwise than in accordance with Form A, Form B or Form C, as the case may be.”.
“7.— (1.) If it is shown to the Director-General that—
(
a ) the approval of a medical practitioner under section 11 of the Act is, or will be, no longer necessary; or(
b )that the approval of a hospital authority under section 12 of the Act in respect of the hospital at which a pharmaceutical chemist is not employed is, or will be, no longer desirable.
by reason of the fact that a pharmaceutical chemist is, or is about to be, approved in respect of premises in the area in relation to which the approval of the medical practitioner was granted, or in the vicinity of the hospital, as the case may be, the Director-General may revoke the approval of the medical practitioner or hospital authority on and from the date specified in the notice of the revocation, being a date after which, in the opinion of the Director-General, the approval will no longer be necessary, or desirable, as the case may be.
“(2.) Before revoking, in accordance with the last preceding sub-regulation, an approval, the Director-General shall—
(
a ) give to the medical practitioner or hospital authority not less than seven days’ notice of his intention to consider the revocation for a reason stated in the notice;(
b )in the notice, invite the medical practitioner or hospital authority to state whether he or it objects to the proposed revocation and, if so, the reasons for the objection; and(
c )consider any objection made by the medical practitioner or hospital authority, and the reasons therefor.
“(3.) Where—
(
a ) a pharmaceutical chemist ceases to carry on business as a pharmaceutical chemist at premises in respect of which he has been approved;(
b )a medical practitioner ceases to practise in the area in respect of which he has been approved; or(
c )a hospital authority ceases to conduct a hospital in respect of which it has been approved,
he or it shall forthwith notify the Director-General accordingly.
“(4.) Where it is shown to the Director-General that—
(
a )a pharmaceutical chemist has ceased to carry on business as a pharmaceutical chemist at premises in respect of which he has been approved;(
b )a medical practitioner has ceased to practise in the area in respect of which he has been approved; or(
c ) a hospital authority has ceased to conduct a hospital in respect of which it has been approved,
the Director-General may revoke the approval.”.
(
a )by omitting the words “, medical practitioner” (wherever occurring); and(
b ) by inserting in paragraph (a ), after the word “he”, the words “or it”.
“11,— (1.) Where a medical practitioner writes a prescription on a prescription form, he shall indicate the pharmaceutical benefit to he supplied—
(
a )where the pharmaceutical benefit is a material or appliance, or is in accordance with a formula other than a formula to which the next succeeding paragraph applies—by the use of the title of that pharmaceutical benefit as specified in the Commonwealth Pharmaceutical Formulary or the addendum thereto; or(
b )where the pharmaceutical benefit is in accordance with a formula deemed by sub-section (2.) of section six of the Act to be included in the Commonwealth Pharmaceutical Formulary—by the use of the title, as specified in that formulary, of the formula to which a permitted variation has been made, and by setting out the variation so made.
“(2.) A medical practitioner who writes a prescription on a prescription form shall—
(
a ) write the prescription in duplicate;(
b )not write more than one other prescription on the prescription form;(
c ) indicate on the prescription form the date on which he writes the prescription; and(
d )draw a line through the unused portion of the prescription form.
“(3.) A medical practitioner shall not use a prescription form otherwise than for the writing of a prescription in accordance with, and for the purposes of, the Act and these Regulations.
“(4.) Where a medical practitioner considers it necessary to write a prescription but a prescription form is not immediately available for that purpose, he may write the prescription on any suitable paper if—
(
a )he indicates on the paper that a prescription form is not available; and(
b )he writes the words ‘Pharmaceutical Benefits Act.’ at the top of the prescription.
“(5.) Where an approved pharmaceutical chemist has supplied a pharmaceutical benefit on presentation of a prescription written by a medical practitioner in accordance with the last preceding sub-regulation, the pharmaceutical chemist—
(
a )shall, as soon as is practicable, request the medical practitioner to furnish to the pharmaceutical chemist, in respect of that pharmaceutical benefit, a prescription written on a prescription form; and(
b )subject to sub-regulation (7.) of this regulation, shall not be entitled to receive payment from the Commonwealth in respect of that pharmaceutical benefit unless he produces with his claim for payment a prescription written on a prescription form.
“(6.) A medical practitioner to whom a request has been made under the last preceding sub-regulation shall, within seven days after he receives the request, comply with the request.
“(7.) If the Director-General is satisfied that the pharmaceutical chemist has been unable to obtain, in accordance with sub-regulation (6.) of this regulation, a prescription written on a prescription form, the Director-General shall, upon a claim for payment being made by the pharmaceutical chemist not earlier than one month after he has, requested the medical practitioner to furnish a prescription written on a prescription form, direct that payment shall be made without the production of a prescription written on a prescription form.
“(8.) A medical practitioner who writes a prescription in accordance with sub-regulation (4.) of this regulation shall not write on the prescription a direction that the pharmaceutical benefit be supplied more than once, and if he does write such a direction, the prescription shall be deemed, for the purposes of the Act and these Regulations, to be a prescription for the supply of the pharmaceutical benefit once only.
“(9.) Subject to these Regulations, a medical practitioner shall not give or send or cause or permit to be given or sent to any person a prescription form (whether signed by him or not) unless he has first written a prescription on the prescription form in accordance with these Regulations.
“(10.) The provisions of the last preceding sub-regulation shall not apply where the prescription form is given or sent to a medical practitioner but the medical practitioner who gives or sends the form or causes or permits the form to be given or sent shall keep a written record of the number appearing on the form and the name and address of the medical practitioner to whom the form was given or sent.
Penalty: Fifty pounds.
“11a. The Director-General shall cause supplies of prescription forms to be available at the offices of the Department of Health in each State or Territory of the Commonwealth and to be furnished to medical practitioners on request made personally or by post.”.
“(4.) An approved pharmaceutical chemist who supplies pharmaceutical benefits on presentation of a prescription form shall write or stamp his name on the back of the original copy of the prescription form, and, if more than one prescription has been written on the form, shall initial, on that original form, the prescription for each pharmaceutical benefit supplied.
(5.) Where an approved hospital authority supplies pharmaceutical benefits on presentation of a prescription form, the person who dispenses or supplies the pharmaceutical benefits on behalf of the hospital authority shall write or stamp his name, together with the name of the hospital authority, on the back of the original copy of the prescription form, and, if more than one prescription has been written on the form, shall initial, on that original form, the prescription for each pharmaceutical benefit supplied.”.
“15.— (1.) Where a prescription directs that a pharmaceutical benefit is to be supplied more than once, that pharmaceutical benefit shall not, unless the prescription otherwise directs, be supplied (whether by the same supplier or by different suppliers) more than once on any one day.
“(2.) Subject to these Regulations, where a prescription directs that a pharmaceutical benefit is to be supplied more than once, the pharmaceutical benefit shall only be supplied the number of times directed in the prescription.
“(3.) An approved pharmaceutical chemist who supplies a pharmaceutical benefit on presentation of—
(
a )a prescription which contains a direction to supply that pharmaceutical benefit more than once; or(
b )a repeat authorization issued in accordance with this sub-regulation,
shall, unless no further supply of the pharmaceutical benefit (after the supply which he is making) is authorized, issue to the person presenting the prescription or repeat authorization a repeat authorization, in a form supplied by the Commonwealth, in respect of each pharmaceutical benefit the further supply of which is authorized, and shall attach the repeat authorization to the duplicate of the prescription.
“(4.) For the purpose of entitling a person to the supply of a pharmaceutical benefit, presentation of the duplicate of a prescription shall be deemed to be presentation and surrender of a prescription if, and only if—
(
a ) there is attached to that duplicate a repeat authorization—
(i) referring to the prescription by its number;
(ii) where the prescription refers to two pharmaceutical benefits—referring to the first-written pharmaceutical benefit by the letter A and the second-written pharmaceutical benefit by the letter B; and
(iii) indicating that the pharmaceutical benefit to be supplied has not been supplied for the full number of times directed in the prescription; and
(
b )the person obtaining the pharmaceutical benefit signs a receipt in accordance with Form G for the pharmaceutical benefit on the back of the repeat authorization and surrenders the repeat authorization to the person supplying the pharmaceutical benefit.
“(5.) An approved pharmaceutical chemist who supplies a pharmaceutical benefit on presentation of a repeat authorization shall write or stamp his name on the back of the repeat authorization.
“16. A person shall not be entitled to obtain a pharmaceutical benefit, being an insulin syringe, unless he furnishes to the person supplying the pharmaceutical benefit a statement signed by him to the effect that—
(
a ) he is receiving insulin treatment and does not possess a hypodermic syringe suitable for the purposes of that treatment; and(
b )he has not been supplied, by virtue of the Act, with a hypodermic syringe, suitable for the injection of insulin, at any time during the period of six months immediately preceding the date of the prescription for the pharmaceutical benefit.
“17. An approved pharmaceutical chemist, an approved medical practitioner or an approved hospital authority shall not supply a pharmaceutical benefit on presentation of a prescription (including the duplicate of a prescription, to which a repeat authorization is attached) written more than six months prior to the date of presentation.”.
(
a )by omitting from sub-regulation (1.) the word “Rates” and inserting in its stead the words “Subject to this regulation, the rates”; and(
b ) by adding at the end of sub-regulation (2.) the words “unless the Director-General, in special circumstances, directs that payment shall be made at a higher rate, in which case payment shall be made at the higher rate accordingly.”.
“33. A medical practitioner treating a person in or at an approved public hospital shall not write a prescription in respect of that treatment on a prescription form supplied by the Commonwealth for the purposes of the Act.
“34. The Director-General may, by notice in writing served on a person (other than a medical practitioner), require that person to deliver up to the Director-General, or to a person specified in the notice, within the time specified in the notice, any unused forms in his possession, being forms supplied to him by or on behalf of the Commonwealth under or for the purposes of the Act or these Regulations, and that person shall comply with the notice.
Penalty: Fifty pounds.”.
(
a ) by omitting all the words from and including the words “In this formulary” to and including the words “may be.” and inserting in their stead the following words:—
“In this formulary—
‘amp.’ means ampoule;
‘c.c.’ means cubic centimetre;
‘fl. oz.’ means fluid ounce of 480 minims;
‘G.’ means gramme;
‘G. of As.’ means gramme of arsenic;
‘gr.’ means grain;
‘I.U.’ means international unit;
‘mg.’ means milligramme;
‘mil.’ means millilitre;
‘min.’ means minim;
‘%’ means per centum;
‘oz.’ means ounce of 480 grains;
‘q.s.’ means
‘U.S.A.’ means United States of America;
‘vols.’ means volumes.
The use in this formulary, in relation to any item or part of an item, of the letters ‘B.P.’, ‘B.P.C.’ or ‘A.P.F.’ indicates that that item or part of an item is to conform to the standards of purity required, in respect of that item or part of an item, by the latest edition of the British Pharmacopoeia, the British Pharmaceutical Codex or the Australian Pharmaceutical Formulary, as the case may be, in which that item or part of an item appears. Where the letters ‘B.P.’, ‘B.P.C.’ or ‘A.P.F’ are not used in relation to an item or part of an item in this formulary, that item or part of an item is to conform to the standards of purity required in respect of that item or part of an item by the latest edition of the British Pharmacopoeia in which that item or part of an item appears.”;
(
b ) by omitting the symbol “+” (wherever occurring);(
c ) by omitting the figures “1932” (wherever occurring);(
d )by omitting all references to quantity or number which are immediately preceded by the symbol “+”, and the letters “Hypo. Tabs.” and the word “Tablets.” appearing above any such references;(
e )by omitting from item AU 4 the figure and letters “1/2 fl. oz.”;(
f ) by omitting items CA 1 and CA 2 and inserting in their stead the following item:—“CA 1 | Kaolin Poultice”;(
g )by omitting from items CR 8A, CR 8B, CR 8C, CR 8D, CR 8E, CR 8F and CR 8G, respectively, the figures and letters “8A”, “8B”, “8C”, “8D”, “8E”, “8F” and “8G”, respectively;(
h )by omitting from item EL 2A the figure and letter “2A”;(
i )by omitting from item GA 3 the figure and letters “4 fl. oz.”;(
j )by omitting from items IJ 55, IJ 56, IJ 57, IJ 58, IJ 59 and IJ 60 the word “Containing” (wherever occurring);(
k )by omitting from item OS 3 the figures, letters and symbols “1 fl. oz. (30 mil.)”;(
l )by omitting from item IS 4 the word, figures and letters “to 1/2 oz.”;(
m ) by omitting from item IR 1 the figure and letters “4 fl. oz.”;(
n ) by omitting from item IR 2 the figure and letters “8 fl. oz.”;(
o )by omitting from item LO 3 the figure and letters “4 fl. oz.”;(
p )by omitting from items LO 7A, LO 7B, LO 7C and LO 7D, respectively, the figures and letters “7A”, “7B”, “7C” and “7D”, respectively;(
q )by omitting from the section headed “1. GENERAL SECTION.” all the words from and including the word “Mixtures.” to and including the words “Tincture of Opium … 30min.” and inserting in their stead the following words:—
“
Allowable Additions.
The following list sets out the names of the drugs which may be included in a formula for a mixture contained in this section of the Formulary. Not more than two such drugs may be included in a formula and the drugs shall not be drugs which
are already contained in the formula. The quantity of any drug which may be included in the formula for any mixture shall not exceed the maximum quantity set out in the following list opposite that drug: —
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
“Allowable Substitutes.
The following list sets out the names of the aromatic waters any one of which may be substituted for an aromatic water specified in a formula for a mixture contained in this section of the Formulary: —
Anise Water B.P.C.
Caraway Water B.P.C.
Chloroform Water.
Cinnamon Water.
Dill Water.
Peppermint Water.
The following list sets out the names of the syrups any one of which may be substituted for a syrup (other than Syrup B.P. )specified in a formula for a mixture contained in this section of the Formulary: —
Neutral Syrup of Lemon A.P.F.
Red Syrup A.P.F.
Syrup of Ginger.
Syrup of Lemon.
Syrup of Orange.
Syrup of Tolut.
Syrup B.P.”; (
r )by omitting from items MS 2, MS 3, MS 5, MS 6, MS 19, MS 26, MS 28, MS 41, MS 50, MS 52, MC 2, MC 3, MC 7, MC 10, MC 12, MC 16, MC 18, MC 24, MC 25, MC 27, MC 29 and MC 32 the word “Syrup” (wherever occurring) and inserting in its stead the word and letters “Syrup B.P.”;(
s ) by omitting the asterisk from item MS 52;(
t ) by omitting from item NB 2 the figures and letters “1/4 fl. oz.”;(
u ) by adding to item OC 3, in the second column, the following words:—
“Atropine Sulphate 2 % in Oculentum Base B.P.”;
(
v )by omitting from item OC 7 the words “Salicylate or Sulphate may be used” and inserting in their stead the words “Physostigmine Salicylate or Sulphate 0.25% in Oculentum Base P.P.”;(
w )by omitting from items PA 3A, PA 3B, PA 3C and PA 3D, respectively, the figures and letters “3A”, “3B”, “30” and “3D”, respectively;(
x )by omitting from item PG 2 the figure and letters “1 fl, oz.”;(
y )by omitting from item PG 10 the figure and letters “2 fl. oz.”;(
z )by omitting from item PU 8 the figures and letters “30 gr.” and inserting in their stead the word, figures and letters “to 30 gr.”;(
aa )by omitting from item SA 3 the figure and letters “2 fl. oz.”;(
ab )by omitting from item SY 1A the figure and letter “1A”;(
ac ) by omitting items LZ 2 and LZ 3;(
ad )by omitting from item TIG 8 the figure and letters “1 oz.”;(
ae )by omitting from items UG 38A, UG 38B, UG 38C and UG 38D, respectively, the figures and letters “38A”, “38B”, “38C” and “38D”, respectively;(
af )by inserting in the section headed “2. CHILDREN’S SECTION.”, after the words “Mixtures for Children .”, the following words:—
“Allowable Substitutes.
The following list sets out the names of the aromatic waters any one of which may be substituted for an aromatic water specified in a formula for a mixture contained in this section of the Formulary: —
The following list sets out the names of the syrups any one of which may be substituted for a syrup (other than Syrup B.P. )specified in a formula for a mixture contained in this section of the Formulary: —
(
ag )by omitting from item BB 7 the words “1 capillary tube containing one dose”;(
ah ) by inserting after item BD 1 the following item:—
“1a | Insulin (Pig) 20 units per mil. 5 mil. vial.”;
(
ai ) by inserting after item BD 2 the following item:—
“2a | Insulin (Pig) 40 units per mil. 5 mil. vial.”;
(
aj ) by inserting after item BD 3 the following item:—
“3a | Insulin (Pig) 60 units per mil. 5 mil. vial.”; and
(
ak )by omitting items BE 1 and BE 2 and inserting in their stead the following item:—
“BE 1 | Penicillin Sulphanilamide—Penicillin 5,000 units per gram.”.
(
a )by inserting after the heading “MEDICAL MATERIALS AND APPLIANCES” the following words:—“
The use in this addendum, in relation to any item, of the letters ‘B.P.C.’ indicates that that item must conform to the standards of composition and purity required in respect of that item by the latest edition of the British Pharmaceutical Codex in which that item appears.”; (
b )by omitting the symbols and figures “+1”, “+2”, “+3” and “+12” (wherever occurring);(
c )by omitting from item DS 10 the figures and letters “2½ yds.” and inserting in their stead the figure and letters “5 yds.”;(
d )by omitting from item DS 11 the figures and letters “21/2 yds.” and inserting in their stead the figure and letters “5 yds.”; and(
e )by omitting from item DS 12 the figure and letters “4 yds.” and inserting in their stead the figure and letters “3 yds.”.
(
a )by omitting paragraphs 1 and 2 and inserting in their stead the following paragraphs:—
“1.—(1.) In this Schedule—
‘prescription code’, in relation to a pharmaceutical benefit, means the letters and number opposite to that pharmaceutical benefit or the formula thereof, or the formula a variation of which constitutes the formula for the pharmaceutical benefit, in the column headed “Prescription Code” in the Second or Third Schedule, as the case may be;
‘quantity or number’ means quantity or number of a pharmaceutical benefit;
‘rate’ means the rate of payment in respect of the supply of a quantity or number;
‘Table A’ means Table A in this Schedule;
‘the scheduled rate’,in relation to the supply of a quantity or number of a pharmaceutical benefit, means the rate in pence applicable to that supply in accordance with clause (
d ) or (e )of the next succeeding sub-paragraph.
(2.) For the purposes of this Schedule—
(
a ) any reference to a column shall be read as a reference to a column in Table A;(
b ) any reference to a paragraph shall be read as a reference to a paragraph in this Schedule;(
c ) any reference to a Schedule shall be read as a reference to a Schedule to these Regulations;(
d )a rate in pence specified in Column 5 shall be applicable to the supply, in a State the name of which is indicated in Column 4 opposite to that rate, of the quantity or number specified in Column 2, opposite to that rate, of the pharmaceutical benefit the prescription code of which is specified in Column 1 opposite to that rate; and(
e ) a rate in pence specified in Column 3 shall be applicable to the supply, in a State other than a State the name of which is indicated in Column 4 opposite to that rate, of the quantity or number specified in Column 2, opposite to that rate, of the pharmaceutical benefit the prescription code of which is specified in Column 1 opposite to that rate.
(3.) The use, in column 4 of Table A, of the letter—
‘N’ indicates the State of New South Wales (including the Australian Capital Territory);
‘V’ indicates the State of Victoria;
‘Q’ indicates the State of Queensland;
‘S’ indicates the State of South Australia (including the Northern Territory);
‘W’ indicates the State of Western Australia; and
‘T’ indicates the State of Tasmania.
“2. The rate in respect of a pharmaceutical benefit supplied at a place situated within Zone 1 shall, subject to paragraphs 9 and 10, he an amount ascertained in accordance with paragraphs 5, 6, 7 and 8.”;
(
b )by omitting from paragraph 3 the words “Subject to this Schedule, the” and inserting in their stead the word “The”;(
c ) by omitting from paragraph 4 the words “Subject to this Schedule, the” and inserting in their stead the word “The”;(
d )by inserting in the table in that paragraph, after the word “Wudinna”, the following words and figures:—
“Victoria |
Omeo | 0.44”;
(
e )by omitting paragraphs 5, 6, 7, 8 and 9 and inserting in their stead the following paragraphs:—“5. Where there is a scheduled rate applicable to the quantity or number supplied, the rate shall be the scheduled rate.
“6. Where there is no scheduled rate applicable to the quantity or number supplied, but that quantity or number is less than the greatest quantity or number for which there is a scheduled rate, the rate shall be the scheduled rate for the quantity or number next greater than the quantity or number supplied for which there is a scheduled rate.
“7.— (1.) Where the quantity or number supplied is greater than the greatest quantity or number for which there is a scheduled rate, the rate shall be—
(
a )in the case of Injectio Insulini B.P., Injectio Insulini Protaminati cum Zinco B.P. and the pharmaceutical benefits specified in the Third Schedule—the amount ascertained by multiplying the scheduled rate for one such pharmaceutical benefit by the number of the pharmaceutical benefits supplied;(
b ) in the case of Cataplasma Kaolini and Suppositorium Glycerini—the current retail price, at a place situated within Zone 1, of the quantity or number supplied;(c) in the case of Cremor Penicillini B.P., Cremor Penicillini Sterilisatus B.P., Inhalatio Amylis Nitritis, Oculentum Penicillini P.P., Pessus Acetarsolis and Unguentum Penicillini B.P., the pharmaceutical benefits included under the headings Injectiones (excluding the part headed ‘C. Rectal’), Pilulae, Tabellae and Trochisci in the section headed ‘1. GENERAL SECTION.’ in the Second Schedule, the pharmaceutical benefits included under the heading Vitaminorum Liquores in the section headed ‘2. CHILDREN’S SECTION.’ in the Second Schedule and the pharmaceutical benefits (other than Injectio Insulini B.P. and Injectio Insulini Protaminati cum Zinco P.P.) included in the section headed ‘3. BIOLOGICAL PRODUCTS.’ in the Second Schedule—the amount ascertained in accordance with the following formula:—
; and
(
d ) in the case of pharmaceutical benefits to which the preceding provisions of this sub-paragraph do not apply—the amount ascertained in accordance with the following formula: —
“(2.) For the purposes of the formulae contained in the last preceding sub-paragraph—
‘A’ means the scheduled rate, for the greatest quantity or number for which there is a scheduled rate, less the appropriate dispensing fee;
‘B’ means the number ascertained by dividing the quantity or number supplied by the greatest quantity or number for which there is a scheduled rate, disregarding any remainder;
‘C’ means the appropriate dispensing fee applicable to the quantity or number supplied;
‘D’ means the scheduled rate for the quantity or number represented by the remainder (if any) disregarded in ascertaining B, less the appropriate dispensing fee;
‘E’ means the quantity or number supplied;
‘F’ means the greatest quantity or number for which there is a scheduled rate.
418/51.—21.
“8. For the purposes of the last preceding paragraph, ‘the appropriate dispensing fee’ in relation to a pharmaceutical benefit means the dispensing fee ascertained in accordance with the following table:—
Name or Class of Pharmaceutical Benefit. | Dispensing Fee in Pence. |
| 14 |
| 15 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 34 |
“9.— (1.) Subject to the next succeeding sub-paragraph, where an allowable additional drug in included in a formula for a pharmaceutical benefit, the rate which would otherwise be payable in respect of the supply of that pharmaceutical benefit shall, in respect of each additional drug so included, be increased by an amount ascertained by multiplying the amount set out in the following table opposite to the name of that drug by the number of ounces or fluid ounces of the pharmaceutical benefit supplied:—
Drug. | Amount in Pence. |
Crude Coal Tar, Liquified Phenol, Phenol, Prepared Coal Tar, Precipitated Sulphur, Solution of Coal Tar, Solution of Glyceryl Trinitrate, Strong Solution of Lead Subacetate | 0.2 |
Brilliant Green, Crystal Violet, Potassium Bromide............................................................ | 0.5 |
Ammoniated Mercury, Tincture of Belladonna, Tincture of Digitalis................................... | 0.7 |
Ichthammol, Sodium Salicylate, Soluble Phenobarbitone.................................................... | 0.9 |
Menthol, Tincture of Nux Vomica..................................................................................... | 1.2 |
Liquid Extract of Cascara Sagrada, Tincture of Opium....................................................... | 3.0 |
Potassium Iodide, Solution of Morphine Hydrochloride...................................................... | 3.3 |
“(2.) In the ease of the inclusion of an allowable additional drug in the formula for a pharmaceutical benefit of which the prescription code is MS 8, MS 15, MS 25, MS 27, MS 29, EL 2 or SY 1, the amount to be added to the rate which would otherwise be payable in respect of that pharmaceutical benefit shall, in respect of each additional drug so included, be four times the amount ascertained in accordance with the last preceding sub-paragraph.”
; and
(
f ) by omitting Table A and Table B and inserting in their stead the following Table:—
TABLE A.
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
Table A—
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
Table A—
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Table A—
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
Table A—
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
Table A—
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
Table A—
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
Table A—
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
Table A—
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Table A—
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
Table A—
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
418/
Table A—
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
Table A—
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Table A—
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
Table A—
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
Table A—
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
Table A—
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
Table A—
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
|
|
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
0
0
0